tiprankstipranks
Advertisement
Advertisement

ARWR Stock Latest News

Arrowhead presents long-term efficacy, safety data for plozasiran
The FlyArrowhead presents long-term efficacy, safety data for plozasiran
21d ago
ARWR
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
PremiumRatings
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
23d ago
ARWR
Wave data brings questions about Arrowhead ‘back to center stage,’ says Leerink
PremiumThe Fly
Wave data brings questions about Arrowhead ‘back to center stage,’ says Leerink
24d ago
WVE
ARWR
Arrowhead price target lowered to $81 from $84 at BofA
PremiumThe Fly
Arrowhead price target lowered to $81 from $84 at BofA
24d ago
ARWR
IONS
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting
PremiumCompany Announcements
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting
29d ago
8K
ARWR
Arrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential
PremiumCompany AnnouncementsArrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential
30d ago
ARWR
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026
Premium
Company Announcements
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026
2M ago
ARWR
Arrowhead price target lowered to $78 from $81 at Morgan Stanley
Premium
The Fly
Arrowhead price target lowered to $78 from $81 at Morgan Stanley
2M ago
ARWR
Arrowhead: Early Redemplo Launch Momentum and De-Risked sHTG Pivotal Program Underpin Attractive Buy Thesis
PremiumRatings
Arrowhead: Early Redemplo Launch Momentum and De-Risked sHTG Pivotal Program Underpin Attractive Buy Thesis
2M ago
ARWR
Arrowhead to replace Ciena in S&P 400 at open on 2/9
PremiumThe Fly
Arrowhead to replace Ciena in S&P 400 at open on 2/9
2M ago
ARWR
CIEN
ADT Inc. to replace Arrowhead in S&P 600 at open on 2/9
PremiumThe Fly
ADT Inc. to replace Arrowhead in S&P 600 at open on 2/9
2M ago
ADT
ARWR
Is ARWR a Buy, Before Earnings?
PremiumPre-Earnings
Is ARWR a Buy, Before Earnings?
2M ago
ARWR
Arrowhead doses first patient in ARO-DIMER-PA trial
PremiumThe FlyArrowhead doses first patient in ARO-DIMER-PA trial
3M ago
ARWR
Arrowhead price target raised to $101 from $61 at B. Riley
Premium
The Fly
Arrowhead price target raised to $101 from $61 at B. Riley
3M ago
ARWR
Arrowhead price target raised to $100 from $85 at H.C. Wainwright
Premium
The Fly
Arrowhead price target raised to $100 from $85 at H.C. Wainwright
3M ago
ARWR
Arrowhead price target raised to $110 from $100 at Piper Sandler
PremiumThe Fly
Arrowhead price target raised to $110 from $100 at Piper Sandler
3M ago
ARWR
Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes
PremiumCompany Announcements
Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes
3M ago
8K
ARWR
Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch
PremiumCompany Announcements
Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch
3M ago
ARWR
Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings
PremiumCompany Announcements
Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings
3M ago
8K
ARWR
Arrowhead 3.1M share Secondary priced at $64.50
PremiumThe FlyArrowhead 3.1M share Secondary priced at $64.50
3M ago
ARWR
Arrowhead announces China NMPA approval for Redemplo
Premium
The Fly
Arrowhead announces China NMPA approval for Redemplo
3M ago
ARWR
Arrowhead price target raised to $85 from $50 at Goldman Sachs
Premium
The Fly
Arrowhead price target raised to $85 from $50 at Goldman Sachs
3M ago
ARWR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >